Othelium Therapeutics 

Cambridge, MA & metabolic, Biologics, Cardiovascular, endocrine, Immunology & inflammation, renal
Overview
Othelium Therapeutics is developing a first-in-class biologic therapy to improve endothelial dysfunction in diabetic kidney disease.
Leadership
  • Tim Hla, PhD

    Investigator, Vascular Biology Program, Boston Children's Hospital; Chair and Professor, Patricia K. Donohoe, Department of Surgery, Harvard Medical School

See all alumni